ID   K562/DNR
AC   CVCL_4T87
DR   Wikidata; Q54899409
RX   PubMed=8787550;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 29-06-23; Version: 15
//
RX   PubMed=8787550; DOI=10.1016/0006-2952(96)00042-1;
RA   Praet M., Stryckmans P., Ruysschaert J.-M.;
RT   "Cellular uptake, cytotoxicity, and transport kinetics of
RT   anthracyclines in human sensitive and multidrug-resistant K562
RT   cells.";
RL   Biochem. Pharmacol. 51:1341-1348(1996).
//